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Purpose
Patients with Down syndrome (DS) have an increased
prevalence of arthritis compared to the general popula-
tion, and often the arthritis is severe and debilitating. In
light of the concern for folate deficiency in this patient
population, and a clinically observed increased risk for
methotrexate (MTX) toxicity, we investigated intracellu-
lar folate concentrations in DS patients on methotrexate
therapy.
Methods
This single center cross-sectional study evaluated 102 JIA
patients on stable doses of MTX, including 4 DS patients,
and 108 patients who were not currently on MTX,
including 15 DS patients. After obtaining informed con-
sent, blood was obtained during routine lab monitoring.
Clinical data was collected by chart review. RBC folate
concentrations were determined after deconjugation and
analyzed via reversed phase separation and stable isotope
dilution tandem mass spectrometry. Measured intracellu-
lar folate isoforms included: 5,10 methenyl tetrahydrofo-
late (5,10-Methenyl THF) which included the isoforms
5 formyl THF, 10 formyl THF, and 5,10 methenyl THF; 5
methyl tetrahydrofolate (5-MTHF) and the sum of the
two. RBC MTX polyglutamate (MTXGlu) concentrations
were measured by ion-pair separation followed by tan-
dem mass spectrometry.
Results
In subjects not on MTX therapy, folate concentrations
(mean nmol/L (± SD)) tended to be lower in DS patients:
5-MTHF [790.1(± 404.2) vs. 1028.9 (± 487.6) P=0.08]; 5,
10-Methenyl THF [55.4 (± 79.5) vs. 92.6 (± 106.5)
P=0.005] and sum of the two [845.5 (± 403.5) vs. 1121.6
(± 512.3) P=0.05]. In subjects receiving MTX, folate
concentrations in the DS patients appeared to be higher:
5-MTHF [1102 (± 153.1) vs. 665.9 (± 274.6) P=0.006];
5,10-Methenyl THF [58.4 (± 78.0) vs. 67.9 (± 76.9)
P=0.4] and sum of the two [1176 (± 195.2) vs. 733.8 (±
287.0) P=0.007]. When the sum folate concentrations
were directly compared in subjects without DS, there was
an expected anti-folate effect in subjects receiving MTX
[733.8 (± 287.0) vs. 1121.6 (± 512.3) P<0.0001]. However,
there was no significant difference in sum folate concen-
trations despite being on MTX in the DS patients
[1176.1 (± 195.2) vs. 845.5 (± 403.5) P=0.09]. All DS
patients on MTX were receiving biologics and had active
arthritis at the time of blood draw. No DS patient
received supplemental folate. Clinical characteristics were
similar, except that DS patients were on lower doses of
MTX [0.26mg/kg (± 0.08) vs. 0.51mg/kg (± 0.24)
P=0.04], and total MTXGlu concentrations, total
MTXGlu concentrations corrected for dose of MTX
administered, and long chain MTXGlu3-5 were not statis-
tically different in DS patients.
Conclusion
Despite intracellular folate concentrations being lower in
DS patients at baseline, there appears to be no signifi-
cant folate inhibition by MTX in this population of
patients. In our cohort of patients with JIA receiving
MTX, those with active arthritis had higher intracellular
folate concentrations, suggesting a less effective anti-
folate effect from MTX. This may also explain the poor
response to MTX in our small population of DS patients
receiving MTX. However, the number of DS patients
receiving MTX in our cohort is small and further
assessment in a larger cohort will be necessary to con-
firm these findings.
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